Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-003835-28
    Sponsor's Protocol Code Number:APHP210089
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-12-14
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2021-003835-28
    A.3Full title of the trial
    Prevention of C. difficile infections with oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a double-blind, randomized, placebo-controlled trial ”
    VANCALLO
    Prévention des infections à C. difficile par vancomycine per os chez des patients pris en charge pour une allogreffe de cellules souches hématopoïétiques, un essai randomisé contre placebo en double aveugle »
    VANCALLO
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Prevention of C. difficile infections with oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a double-blind, randomized, placebo-controlled trial ”
    VANCALLO
    Prévention des infections à C. difficile par vancomycine per os chez des patients pris en charge pour une allogreffe de cellules souches hématopoïétiques, un essai randomisé contre placebo en double aveugle »
    VANCALLO
    A.3.2Name or abbreviated title of the trial where available
    VANCALLO
    VANCALLO
    A.4.1Sponsor's protocol code numberAPHP210089
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportInterregional Clinical Research and Innovation Group (GIRCI) of Ile-de-France (DGOS, PHRC I 2020)
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS
    B.5.2Functional name of contact pointLEMADRE
    B.5.3 Address:
    B.5.3.1Street AddressDirection de la Recherche Clinique et de l'Innovation, Hôpital Saint-Louis, 1 ave Claude Vellefaux
    B.5.3.2Town/ cityPARIS
    B.5.3.3Post code75010
    B.5.3.4CountryFrance
    B.5.4Telephone number+331 44 84 17 34
    B.5.5Fax number+33 1 44 84 17 01
    B.5.6E-mailelodie.lemadre@aphp.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVANCOMYCIN
    D.3.4Pharmaceutical form Powder for oral solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVANCOMYCIN
    D.3.9.1CAS number 1404-90-6
    D.3.9.4EV Substance CodeSUB05076MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients hospitalized for an allogeneic hematopoietic stem cell transplant
    Patients hospitalisés pour une allogreffe de cellules souches hématopoïétiques
    E.1.1.1Medical condition in easily understood language
    Patients hospitalized for an allogeneic hematopoietic stem cell transplant
    Patients hospitalisés pour une allogreffe de cellules souches hématopoïétiques
    E.1.1.2Therapeutic area Diseases [C] - Bacterial Infections and Mycoses [C01]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10059044
    E.1.2Term Allogeneic peripheral hematopoietic stem cell transplant
    E.1.2System Organ Class 100000004865
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of oral vancomycin prophylaxis in preventing Clostridium difficile infections in patients hospitalized for allogeneic HSC transplantation.
    Evaluer l’efficacité d’une prophylaxie par vancomycine orale sur la prévention des infections à Clostridium difficile chez les patients hospitalisés pour une allogreffe de CSH.
    E.2.2Secondary objectives of the trial
    In HSCT patients, assess the impact of oral vancomycin prophylaxis on:
    - Prevention of CD infections occurring after stopping prophylaxis (qsp S12)
    - Prevention of CD infections in hospitalized patients for HSCT (qsp S5)
    - Prevention of CD infections in hospitalized patients with a diagnosis made by PCR detection of the toxigenic strain
    - Severity of CD infections occurring during treatment
    - Risk factors for CD infection: antibiotics received, presence of toxigenic strain on D0 of treatment, composition of the microbiota
    - Profile of bacterial infections occurring during treatment with vancomycin
    - Impact of the treatment on the intestinal microbiota
    - Emergence of enterococcus resistant to vancomycin
    - Occurrence of nosocomial clusters of CD infection up to W12
    - Onset of acute or chronic GVHD
    - Relapse of hematological disease
    - MRT linked to the transplant procedure at 1 month
    - Overall survival at M12
    Chez les patients HSCT, évaluer l’impact d’une prophylaxie par vancomycine orale sur :
    - Prévention des infections à CD survenant après arrêt de la prophylaxie (qsp S12)
    - Prévention des infections à CD chez les patients hospitalisés pour HSCT (qsp S5)
    - Prévention des infections à CD chez les patients hospitalisés avec un diagnostic porté par la détection par PCR de la souche toxinogène
    - Gravité des infections à CD survenant sous traitement
    - Facteurs de risque de survenue d’infection à CD : antibiotiques reçus, présence de souche toxinogène à J0 de traitement, composition du microbiote
    - Profil des infections bactériennes survenant en cours de traitement par vancomycine
    - Impact du traitement sur le microbiote intestinal
    - Emergence d’entérocoque résistant à la vancomycine
    - Survenue de clusters nosocomiaux d’infection à CD jusqu’à S12
    - Survenue de GVH aigue ou chronique
    - Rechute de la maladie hématologique
    - TRM liée à la procédure de greffe à 1 mois
    - Survie globale à M12
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    An ancillary study will aim to assess the impact of treatment with oral vancomycin on the intestinal microbiota in allogeneic HSC transplant patients.
    Indeed, it has been demonstrated that the composition of the intestinal microbiota can influence the development of CD infections with an excess of species belonging to Enterococcus and a depletion of Ruminococcus, Blautia, Prevotella and Bifidobacterium in the stools of patients with CD infection. But above all, the occurrence of a CD infection can modify the intestinal microbiota for the benefit of certain organisms belonging to Bacteroidetes, Firmicutes, Proteobacteria, Ascomycota, and Opalinata. We will therefore be interested in the search for risk factors linked to the intestinal microbiota that can identify patients at greater risk of CD infection and also to the repercussions of both vancomycin treatment and the possible occurrence of CD infection. . In addition, we will look a posteriori for the asymptomatic carriage of toxigenic CD before initiation of treatment to assess whether this is predictive of the risk of presenting a CD infection as suggested by a recent study.
    Une étude ancillaire aura pour but d’évaluer l’impact d’un traitement par vancomycine orale sur le microbiote intestinal chez le patient allogreffé de CSH.
    En effet, il a été mis en évidence que la composition du microbiote intestinal peut influencer le développement d’infections à CD avec un excès d’espèces appartenant à Enterococcus et une déplétion en Ruminococcus, Blautia, Prevotella et Bifidobacterium dans les selles des patients présentant une infection à CD. Mais surtout la survenue d’une infection à CD peut modifier le microbiote intestinal au profit de certains organismes appartenant aux Bacteroidetes, Firmicutes, Proteobacteria, Ascomycota, et Opalinata. Nous nous intéresserons donc à la recherche de facteurs de risque liés au microbiote intestinal pouvant permettre d’identifier des patients plus à risque d’infection à CD et aussi au retentissement tant du traitement par vancomycine que de l’éventuelle survenue d’infection à CD. Par ailleurs, nous rechercherons a posteriori le portage asymptomatique de CD toxinogène avant initiation du traitement pour évaluer si celui ci est prédictif du risque de présenter une infection à CD comme suggéré par une étude récente.
    E.3Principal inclusion criteria
    - Age ≥15 years
    - Patient hospitalized for less than 72 hours to receive an allogeneic CSH transplant, regardless of the indication and the packaging,
    - for men and women of childbearing age: use of effective contraception
    - Have given their consent to participate in the study.
    - Beneficiary of health insurance
    - Age ≥15 ans
    - Patient hospitalisé depuis moins de 72h pour recevoir une allogreffe de CSH, quels que soient l’indication et le conditionnement,
    - pour les hommes et pour les femmes en âge de procréer : utilisation de contraception efficace
    - Avoir donné son consentement pour la participation à l’étude.
    - Bénéficiaire d’une assurance maladie
    E.4Principal exclusion criteria
    - Documented allergy or side effects to vancomycin
    - Pregnancy and breast feeding
    - Clostridium difficile infection within 30 days prior to inclusion or on the day of inclusion
    - History of total colectomy and / or chronic inflammatory bowel disease
    - Active diarrhea on inclusion regardless of the aetiology
    - Digestive decontamination protocol during the transplant procedure
    - Participation in another drug intervention research involving the human person or being in the exclusion period following a previous research involving the human person, if applicable
    - Allergie documentée ou effets indésirables à la vancomycine
    - Grossesse et allaitement
    - Infection à Clostridium difficile dans les 30 jours précédant l’inclusion ou le jour de l’inclusion
    - Antécédent de colectomie totale et/ou de maladie inflammatoire chronique de l’intestin
    - Diarrhée évolutive à l’inclusion quelle que soit l’étiologie
    - Protocole de décontamination digestive lors de la procédure de greffe
    - Participation à une autre recherche interventionnelle médicamenteuse impliquant la personne humaine ou être dans la période d’exclusion à l’issue d’une précédente recherche impliquant la personne humaine, le cas échéant
    E.5 End points
    E.5.1Primary end point(s)
    Clostridium difficile infection, occurring between inclusion and discharge from hospital or the end of treatment with vancomycin (i.e. after 5 weeks of treatment (W5) if the patient is still hospitalized), defined by diarrhea (> 3 stools not formed / day) with detection of CD (GDH) and free toxin in the stool by enzyme-linked immunosorbent assay without evidence for another etiology to diarrhea or existence of pseudomembranous colitis at endoscopy, colectomy or autopsy
    Infection à Clostridium difficile, survenant entre l’inclusion et la sortie d’hospitalisation ou la fin du traitement par vancomycine (soit après 5 semaines de traitement (S5) si le patient est toujours hospitalisé), définie par une diarrhée (> 3 selles non formées/jour) avec détection de CD (GDH) et de toxine libre dans les selles par méthode immuno-enzymatique sans argument pour une autre étiologie aux diarrhées ou existence d’une colite pseudo-membraneuse à l’endoscopie, à la colectomie ou à l’autopsie.
    E.5.1.1Timepoint(s) of evaluation of this end point
    D0 and W5
    J0 et S5
    E.5.2Secondary end point(s)
    - Clostridium difficile infection, occurring between inclusion and W12, defined by diarrhea (> 3 unformed stools / day) with detection of CD and free toxin in the stool by enzyme-linked immunosorbent assay without evidence for another etiology. diarrhea or existence of pseudomembranous colitis on endoscopy, colectomy or autopsy.
    - Time between inclusion and Clostridium difficile infection, occurring between inclusion and discharge from hospital or the end of treatment with vancomycin (i.e. after 5 weeks of treatment (W5) if the patient is still hospitalized), defined by diarrhea (> 3 unformed stools / day) with detection of CD (GDH) and free toxin in the stool by enzyme immunoassay without argument for another etiology to diarrhea or existence of pseudomembranous colitis with endoscopy, colectomy or autopsy or delay in hospital follow-up (for patients discharged or died without infection), at most at W5
    - Clostridium difficile infection, occurring between inclusion and discharge from hospital or the end of treatment with vancomycin (i.e. after 5 weeks of treatment (W5) if the patient is still hospitalized), defined by diarrhea (> 3 stools not formed / day) with detection of toxinogenic CD by PCR without argument for another etiology to diarrhea or existence of pseudomembranous colitis at endoscopy, colectomy or autopsy.
    - Risk factors for CD infection: antibiotics received, presence of toxigenic strain on D0 of treatment (D0V), composition of the microbiota
    - Severity factors for CD infections occurring during the procedure
    - Documented bacterial infection (s) (regardless of the infectious focus) occurring during treatment with vancomycin (up to a maximum of 5 weeks)
    - Acquisition of rectal carriage of Vancomycin-resistant Enterococcus (VRE) between randomization and the end of treatment (discharge from hospital or maximum S5) measured by rectal swabbing
    - Study of the intestinal microbiota at inclusion, during treatment (14 days after initiation of treatment, i.e. S2), at the end of treatment (W5 or before discharge from hospital) and at a distance (S12)
    - Occurrence of nosocomial clusters of CD at W12 infection defined as the occurrence of at least 2 cases of CDI over a period of time defined according to the incidence usually observed in the investigating center
    - Occurrence of acute or chronic GVHD grade 2-4 to M12
    - Time between inclusion and relapse of the hematological disease, or the date of the latest news (maximum M12)
    - Mortality rate linked to the transplant procedure (TRM) at W5
    - Time between inclusion and death, or the date of the latest news (maximum M12).
    - Infection à Clostridium difficile, survenant entre l’inclusion et S12, définie par une diarrhée (> 3 selles non formées/jour) avec détection de CD et de toxine libre dans les selles par méthode immuno-enzymatique sans argument pour une autre étiologie aux diarrhées ou existence d’une colite pseudo-membraneuse à l’endoscopie, à la colectomie ou à l’autopsie.
    - Délai entre l’inclusion et l’infection à Clostridium difficile, survenant entre l’inclusion et la sortie d’hospitalisation ou la fin du traitement par vancomycine (soit après 5 semaines de traitement (S5) si le patient est toujours hospitalisé), définie par une diarrhée (> 3 selles non formées/jour) avec détection de CD (GDH) et de toxine libre dans les selles par méthode immuno-enzymatique sans argument pour une autre étiologie aux diarrhées ou existence d’une colite pseudo-membraneuse à l’endoscopie, à la colectomie ou à l’autopsie ou délai de suivi hospitalier (pour les patients sortis ou décédés sans infection), au maximum à S5
    - Infection à Clostridium difficile, survenant entre l’inclusion et la sortie d’hospitalisation ou la fin du traitement par vancomycine (soit après 5 semaines de traitement (S5) si le patient est toujours hospitalisé), définie par une diarrhée (> 3 selles non formées/jour) avec détection de CD toxinogène par PCR sans argument pour une autre étiologie aux diarrhées ou existence d’une colite pseudo-membraneuse à l’endoscopie, à la colectomie ou à l’autopsie.
    - Facteurs de risque d’infection à CD : antibiotiques reçus, présence de souche toxinogène à J0 de traitement (J0V), composition du microbiote
    - Facteurs de gravité des infections à CD survenant pendant la procédure
    - Infection(s) bactérienne(s) documentée(s) (quel que soit le foyer infectieux) survenant en cours de traitement par vancomycine (soit jusqu’à 5 semaines au maximum)
    - Acquisition du portage rectal d’Entérocoque résistant à la vancomycine (ERV) entre la randomisation et la fin de traitement (sortie d’hospitalisation ou S5 au maximum) mesurée par écouvillonnage rectal
    - Etude du microbiote intestinal à l’inclusion, pendant le traitement (14 jours après initiation du traitement soit S2), en fin de traitement (S5 ou avant la sortie d’hospitalisation) et à distance (S12)
    - Survenue de clusters nosocomiaux d’infection à CD à S12 définis comme la survenue d’au moins 2 cas d’ICD sur une période de temps définie en fonction de l’incidence habituellement observée dans le centre investigateur
    - Survenue de GVH aiguë ou chronique de grade 2-4 à M12
    - Délai entre l’inclusion et la rechute de la maladie hématologique, ou la date de dernières nouvelles (au maximum M12)
    - Taux de mortalité liée à la procédure de greffe (TRM) à S5
    - Délai entre l’inclusion et le décès, ou la date de dernières nouvelles (au maximum M12).
    E.5.2.1Timepoint(s) of evaluation of this end point
    D0, W2, W5, W12 and M12
    J0, S2, S5, S12 et M12
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    DVDS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 33
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 270
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 33
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state336
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Normal treatment expected
    Traitement normal attendu
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-02-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-02-17
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 09:25:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA